Aspire Biopharma to Acquire Automotive Supplier with $200M Revenue for $30M Cash
Aspire Biopharma signed a non-binding letter of intent to acquire Dura Driver Control Systems for $30 million in cash, adding a tier-one automotive supplier with over $200 million in 2025 revenue and $22 million in adjusted EBITDA. DCS brings 310 patents, 11 global manufacturing sites and relationships across 150 vehicle platforms.
1. Acquisition Terms
Aspire Biopharma has entered into a non-binding letter of intent to purchase 100% of Dura Driver Control Systems for $30 million in cash, subject to completion of due diligence and a full U.S. GAAP audit of DCS’s financials. The agreement outlines cash payment upon closing and customary conditions including regulatory approvals and final agreements.
2. DCS Financial and Operations Profile
Dura Driver Control Systems delivered more than $200 million in revenue and over $22 million in adjusted EBITDA for fiscal 2025, with net income exceeding $17 million. The supplier operates 11 global facilities, serves over 150 vehicle platforms for major OEMs, maintains a portfolio of more than 310 patents, and employs 55 dedicated design and product engineers.
3. Strategic Rationale
The acquisition marks a transformative shift for Aspire, providing immediate high-revenue diversification beyond its biopharmaceutical pipeline. DCS’s deep IP portfolio and blue-chip customer base support potential cross-industry expansion and stable cash flow generation for the combined enterprise.